An itching sensation can be an early warning sign of a skin reaction, such as a rash. Auranofin also can cause a metallic taste and mouth sores, though less frequently than injectable gold salts. Because gold salts can cause serious kidney and bone marrow problems, all patients require monitoring with regular testing of blood and urine. Hair loss, anemia, and reduced number of white blood cells or platelets have also been reported.
GENERIC AVAILABLE: No
PREPARATIONS: Capsule: 3 mg.
STORAGE: Auranofin should be stored between 15 C and 30 C (59 F and 86 F) and dispensed in a tight, light-resistant container
DOSING: The usual adult dosage of auranofin is 3 mg twice daily or 6 mg once a day. The dose may be increased to 3 mg three times daily after three months.
DRUG INTERACTIONS: The concurrent use of auranofin and phenytoin (Dilantin), an antiepileptic drug, may increase phenytoin blood levels, which may lead to phenytoin toxicity for unclear reasons. The concurrent use of penicillamine (Cuprimine, Depen) and gold salts may result in blood cell or kidney toxicity since both drugs are toxic to the blood cells and kidney. The auranofin should not be used with atovaquone/proguanil (Malarone) an antimalarial drug, as the combination may increase the risk of toxicity to blood cells.
PREGNANCY: There are no adequate studies in pregnant women. Use of auranofin in pregnant women is not recommended.
NURSING MOTHERS: Auranofin has been found in the breast milk of nursing mothers. Nursing during auranofin therapy is not recommended.
Medically reviewed by Eni Williams, PharmD
Reference: FDA Prescribing Information
Quick GuideRheumatoid Arthritis (RA) Pictures Slideshow
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.